Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002957356 | SCV003270910 | uncertain significance | NIK deficiency | 2022-01-02 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs760322653, gnomAD 0.02%). This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 107 of the MAP3K14 protein (p.Gln107Arg). This variant has not been reported in the literature in individuals affected with MAP3K14-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. |
Ambry Genetics | RCV004642076 | SCV005137790 | uncertain significance | not specified | 2024-05-20 | criteria provided, single submitter | clinical testing | The c.320A>G (p.Q107R) alteration is located in exon 3 (coding exon 2) of the MAP3K14 gene. This alteration results from a A to G substitution at nucleotide position 320, causing the glutamine (Q) at amino acid position 107 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |